Drugs Made In America Acquisition Corp. Units (DMAAU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Drugs Made In America Acquisition Corp. Units (DMAAU) has a cash flow conversion efficiency ratio of -0.001x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-125.18K) by net assets ($232.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Drugs Made In America Acquisition Corp. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Drugs Made In America Acquisition Corp. Units - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Drugs Made In America Acquisition Corp. Units's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Drugs Made In America Acquisition Corp. Units Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Drugs Made In America Acquisition Corp. Units ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nanjing OLO Home Furnishing
SHG:603326
|
0.053x |
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
-0.192x |
|
Zhejiang Giuseppe Garment Co Ltd
SHE:002687
|
0.041x |
|
Edda Wind ASA
OL:EWIND
|
0.018x |
|
Polaris Media
OL:POL
|
0.072x |
|
Huizhong Instrumentation Co Ltd
SHE:300371
|
0.054x |
|
Bukwang Pharm
KO:003000
|
-0.018x |
|
D. Boral Acquisition I Corp. Class A Ordinary Shares
NASDAQ:DBCA
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Drugs Made In America Acquisition Corp. Units (2024–2025)
The table below shows the annual cash flow conversion efficiency of Drugs Made In America Acquisition Corp. Units from 2024 to 2025. For the full company profile with market capitalisation and key ratios, see Drugs Made In America Acquisition Corp. (DMAAU) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $232.64 Million | $-539.19K | -0.002x | -100.00% |
| 2024-12-31 | $-244.85 | $-172.26K | 703.553x | -- |
About Drugs Made In America Acquisition Corp. Units
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.